The initiation of a Phase 2b trial for Halneuron® is a significant milestone for Dogwood Therapeutics, as it targets a substantial $1.5 billion market for chemotherapy-induced neuropathic pain. The opioid-free nature of the treatment is particularly relevant given the current focus on non-addictive pain management solutions. This development is likely to positively impact DWTX's stock price in the short term as it progresses through clinical trials.